Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment
Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.
Aim(s): As anthracycline-containing regimens including either doxorubicin or epi-doxorubicin plus vincristine and cyclophosphamide (ACO or EPICO) are commonly being used, patients have also been treated with these regimens at our institution.
Materials and methods: We have retrospectively analysed patients undergoing 2nd-line therapy after cis/eto. We identified 14 patients treated either with ACO (n=2) or EPICO (n=12). The majority of patients had metastatic NEC originating in the pancreas (n=9), the colon (n=2), and the stomach (n=1); two had unknown primary. The Ki-67 index was 25%-90%; all patients had liver metastasis.
Conference: 12th Annual ENETSConcerence (2015)
To read the full abstract, please log into your ENETS Member account.